Represents the agreement termination period.

No definition available.

Name:	capr_AgreementTerminationPeriod
Namespace Prefix:	capr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount paid for royalties on an annual basis.

+ References

No definition available.

+ Details

Name:	capr_AnnualPaymentsForRoyalties
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

+ References

No definition available.

+ Details

Name:	capr_LicenseAgreementsLineItems
Namespace Prefix:	capr_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of milestone payments during the period.

+ References

No definition available.

+ Details

Name:	capr_MilestonePayments
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments to be made upon successful completion of certain phases as per License agreement.

+ References

No definition available.

+ Details

Name:	capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Period for which agreement will be effective.

+ References

No definition available.

+ Details

Name:	capr_PeriodOfAgreementWillBeInEffective
Namespace Prefix:	capr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of potential additional development and sales based milestone payments payable.

+ References

No definition available.

+ Details

Name:	capr_PotentialAdditionalDevelopmentAndSalesBasedMilestonePayments
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payments payable under the JHU License Agreement.

+ References

No definition available.

+ Details

Name:	capr_PotentialMilestonePayments
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of share of product revenue.

+ References

No definition available.

+ Details

Name:	capr_ShareOfProductRevenuePercentage
Namespace Prefix:	capr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Threshold period to cure breach.

+ References

No definition available.

+ Details

Name:	capr_ThresholdPeriodToCureBreach
Namespace Prefix:	capr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payment made during the period

+ References

No definition available.

+ Details

Name:	capr_UpfrontPayment
Namespace Prefix:	capr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

These lines are represents that notice period.

+ References

No definition available.

+ Details

Name:	capr_WrittenNoticePeriod
Namespace Prefix:	capr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_GrantsReceivableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=capr_BindingTermSheetWithNipponShinyakuCoLimitedEuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=capr_RomeLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=capr_JhuLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=capr_CsmcLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=capr_ExosomesLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	capr_MilestonePaymentsInPhasesAxis=capr_ObtentionOfFdaApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	capr_MilestonePaymentsInPhasesAxis=capr_CompletionOfPhaseTwoDueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	capr_MilestonePaymentsInPhasesAxis=capr_SecondMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AND DISTRIBUTION AGREEMENTS (Details)		1 Months Ended		3 Months Ended			6 Months Ended			12 Months Ended
LICENSE AND DISTRIBUTION AGREEMENTS (Details)	Sep. 16, 2024 USD ($)	Dec. 31, 2024 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2025 EUR (€)	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jan. 24, 2022 USD ($)
LICENSE AGREEMENTS
Revenue					$ 3,971,438				$ 8,878,315
Deferred revenue, current		$ 12,000,000		$ 12,000,000			$ 12,000,000			$ 12,000,000
Receivables		10,368,489		59,509			59,509			10,368,489
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States
LICENSE AGREEMENTS
Potential milestone payments													$ 80,000,000
Milestones paid		10,000,000									$ 10,000,000
Upfront payment												$ 30,000,000
Deferred revenue liability		0		0			0			0
Revenue				0	$ 4,000,000		0		$ 8,900,000	40,000,000
Receivables		$ 10,000,000								10,000,000
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan
LICENSE AGREEMENTS
Potential milestone payments				89,000,000			89,000,000
Upfront payment						$ 12,000,000
Deferred revenue liability				12,000,000			12,000,000
Deferred revenue, current				12,000,000			12,000,000
Binding Term Sheet With Nippon Shinyaku Co Limited Europe
LICENSE AGREEMENTS
Upfront payment	$ 20,000,000
Potential additional development and sales-based milestone payments	$ 715,000,000
CSMC \| Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States
LICENSE AGREEMENTS
Deferred revenue liability				40,000,000			$ 40,000,000
Rome License Agreement
LICENSE AGREEMENTS
Notice period							90 days	90 days
JHU License Agreement
LICENSE AGREEMENTS
Notice period							60 days	60 days
Threshold period to cure breach							30 days	30 days
CSMC License Agreement
LICENSE AGREEMENTS
Notice period							90 days	90 days
Exosomes License Agreement
LICENSE AGREEMENTS
Notice period							90 days	90 days
Minimum \| Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States
LICENSE AGREEMENTS
Share of product revenue (in percent)													30.00%
Minimum \| Rome License Agreement
LICENSE AGREEMENTS
Minimum annual royalty payments \| €								€ 20,000
Maximum \| Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States
LICENSE AGREEMENTS
Share of product revenue (in percent)													50.00%
Potential additional development and sales-based milestone payments													$ 605,000,000
Maximum \| JHU License Agreement
LICENSE AGREEMENTS
Potential milestone payments				1,850,000			$ 1,850,000
Obtention of FDA Approval \| JHU License Agreement
LICENSE AGREEMENTS
Milestone payments to be made upon completion of certain phases				1,000,000			1,000,000
Completion Of Phase Two Due \| JHU License Agreement
LICENSE AGREEMENTS
Milestones paid			$ 250,000
Milestone payments to be made upon completion of certain phases				$ 500,000			$ 500,000
Second Milestone Payment \| Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States
LICENSE AGREEMENTS
Revenue										$ 10,000,000
Patent rights \| JHU License Agreement
LICENSE AGREEMENTS
Agreement effective period							20 years	20 years
Non Payment of Royalties \| CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period							30 days	30 days
Non Payment of Royalties \| Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach							30 days	30 days
CSMC Agreement Compliance \| CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period							90 days	90 days
CSMC Agreement Compliance \| Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach							90 days	90 days
Material Breach Has Not Been Cured \| CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period							90 days	90 days
Material Breach Has Not Been Cured \| Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach							90 days	90 days
Fails To Cure Breach after Notice From CSMC \| CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period							90 days	90 days
Fails To Cure Breach after Notice From CSMC \| Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach							90 days	90 days